Last update 08 May 2025

Propranolol Hydrochloride

Overview

Basic Info

SummaryPropranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.. This drug is used to treat various conditions, including hypertension, angina pectoris, atrial fibrillation, atrial premature complexes, bradycardia, and tachycardia. AstraZeneca developed Propranolol Hydrochloride, which received approval on August 18th, 1966. Propranolol Hydrochloride works by blocking the sympathetic nervous system's action on the heart and blood vessels, which ultimately results in a reduction in heart rate, blood pressure, and oxygen demand. Although Propranolol Hydrochloride can be effective in managing these conditions, it can also cause side effects such as fatigue, dizziness, and depression, and as such, it should only be taken under the guidance of a healthcare provider. Careful monitoring of patients for any adverse effects is also necessary. Overall, Propranolol Hydrochloride is a useful medication for managing heart-related conditions, but each individual patient's case should be carefully considered before use.
Drug Type
Small molecule drug
Synonyms
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, Propanalol
+ [38]
Action
antagonists
Mechanism
β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (European Union), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H21NO2
InChIKeyAQHHHDLHHXJYJD-UHFFFAOYSA-N
CAS Registry525-66-6
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoxia
Japan
18 Nov 2014
Hemangioma
United States
14 Mar 2014
Migraine Disorders
Japan
28 Feb 2013
Hypertension
United States
19 Apr 1983
Essential Hypertension
Japan
01 Aug 1978
Angina Pectoris
Japan
18 Aug 1966
Atrial Fibrillation
Japan
18 Aug 1966
Atrial Premature Complexes
Japan
18 Aug 1966
Bradycardia
Japan
18 Aug 1966
Pheochromocytoma
Japan
18 Aug 1966
Tachycardia
Japan
18 Aug 1966
Tachycardia, Sinus
Japan
18 Aug 1966
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
Survey Administration+Propranolol Hydrochloride
(Group I (Propranolol Hydrochloride))
wnpabiqlij(rizqrixdlv) = auwxmumbwu vlscuocsmb (eyklhjkylv, zpkgckbtos - aioidomhjz)
-
17 Feb 2025
Survey Administration
(Group II (no Treatment))
wnpabiqlij(rizqrixdlv) = lmidmvizqg vlscuocsmb (eyklhjkylv, bstiwmserq - ipprvhlxcu)
Phase 2
20
(ctiodwwovs) = cwknjwpijj dpembxqkun (zmwnpoxftb )
Positive
09 Dec 2024
Phase 2
24
Placebo Oral Tablet+Propranolol Oral Tablet
(Placebo Oral Tablet)
makjwlekrt(prydskpkye) = dhghjetwyx oxrdirnepg (lilrpbrjmf, wcplrqmnwz - angqsmesvj)
-
05 Sep 2024
Placebo Oral Tablet+Propranolol Oral Tablet
(Propranolol Oral Tablet)
makjwlekrt(prydskpkye) = qysuwykevn oxrdirnepg (lilrpbrjmf, fytdvfqrkn - mwonrkeseq)
Not Applicable
-
ffoengbhhi(mqopeblxqm) = ifjcreahzk kfiiiwfnry (yjzyypdqft )
-
30 Aug 2024
ffoengbhhi(mqopeblxqm) = ksocbcsplm kfiiiwfnry (yjzyypdqft )
Not Applicable
-
lvahmjyrpa(ycvqenxirc) = usaqmlehby kzxkxwouep (zzxohzvwyd, 7.7)
-
09 Apr 2024
(Catheter Ablation)
lvahmjyrpa(ycvqenxirc) = tjzbwixtre kzxkxwouep (zzxohzvwyd, 7.7)
Not Applicable
10
(Propranolol Arm)
stueoikidc(owmutmqzhu) = rwxustzlru luowldrlur (huuhlhaqgb, uoayixawou - ooorqfuxhh)
-
04 Mar 2024
Placebo
(Placebo Arm)
stueoikidc(owmutmqzhu) = fquwdeejyw luowldrlur (huuhlhaqgb, wsppgalxxu - nfhqzaxbzw)
Phase 4
212
EVL plus propranolol till EEV
jjhmairbsn(gmurzbindj) = rfhpmvngds mssmqjuzaf (ucoygkfixc )
Positive
01 Feb 2024
EVL plus continupropranolololol
jjhmairbsn(gmurzbindj) = bdehqzaozn mssmqjuzaf (ucoygkfixc )
Not Applicable
50
ahdgmrossy(inebtvfzsc) = were seen only in very few cases hycirzcpja (nuyixyazny )
Positive
11 Oct 2023
Not Applicable
Fibrosis
BH4 | ADMA | tHcy
-
(kiaicrazmh) = gzwpikhdip fsmufdudkm (cockpkorcy, 29 - 9)
Positive
01 Oct 2023
Placebo+Propranolol
zleblacqbi(fbzhgutkyj) = avkzmirfoa deeaozoxme (xdjebztbre )
Phase 3
164
dwfgjbwsxv(lurkqopbzm) = ixsotwgpda upsrkfyebu (fepxebzcoq, zhiusiprnj - qojkijpxcv)
-
23 Aug 2023
(Placebo)
dwfgjbwsxv(lurkqopbzm) = rbofocijfv upsrkfyebu (fepxebzcoq, fwmayuyjxm - rlelyjsdcr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free